{"version":"1.0","provider_name":"Okuvision","provider_url":"https:\/\/okuvision.de\/fr\/","author_name":"Melanie Broll","author_url":"https:\/\/okuvision.de\/fr\/news\/author\/melanie-broll\/","title":"Communiqu\u00e9 de presse - Marquage CE pour OkuStim\u00ae 2","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"gwu7MJsXVe\"><a href=\"https:\/\/okuvision.de\/fr\/news\/pm-os2\/\">Communiqu\u00e9 de presse &#8211; Marquage CE pour OkuStim\u00ae 2<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/okuvision.de\/fr\/news\/pm-os2\/embed\/#?secret=gwu7MJsXVe\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Communiqu\u00e9 de presse &#8211; Marquage CE pour OkuStim\u00ae 2\u00a0\u00bb &#8212; Okuvision\" data-secret=\"gwu7MJsXVe\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/okuvision.de\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/okuvision.de\/wp-content\/uploads\/2025\/12\/OS2_02.webp","thumbnail_width":1350,"thumbnail_height":899,"description":"Okuvision lance OkuStim\u00ae 2, une plateforme th\u00e9rapeutique innovante permettant aux patients de r\u00e9aliser le traitement de la r\u00e9tinite pigmentaire \u00e0 domicile. Le neurostimulateur pour l'\u00e9lectrostimulation transcorn\u00e9enne, dot\u00e9 du marquage CE actuel conform\u00e9ment au r\u00e8glement europ\u00e9en sur les dispositifs m\u00e9dicaux (MDR), a \u00e9t\u00e9 r\u00e9compens\u00e9 par le German Design Award 2026 (Or) pour son design ergonomique."}